There are currently 154 active clinical trials seeking participants for Cardiovascular Diseases research studies. The states with the highest number of trials for Cardiovascular Diseases participants are Florida, California, Texas and New York.
Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
NCT04467671
Recruiting
A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
Gender:
All
Ages:
All
Trial Updated:
05/03/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: HLH - Hypoplastic Left Heart Syndrome, DORV, DILV - Double Inlet Left Ventricle, Mitral Atresia, Tricuspid Atresia, Unbalanced AV Canal, Single-ventricle, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases
Register for Updates
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
NCT06055036
Recruiting
Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body mass index, smoking, glycemia) and Life's Essential 8 (LE8; LS7+sleep) metrics, is a major contributor to Black men having the shortest life-expectancy of any non-indigenous race/sex group. Unfortunately, a paucity of literature exists on interventions aimed at improving CVH among Black men. The team of clinician scientist... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Cardiometabolic Syndrome, Physical Inactivity, Hypertension, Type 2 Diabetes, PreDiabetes, Obesity, Cardiovascular Diseases, Smoking, Sleep, Hyperlipidemias, Diet, Healthy, Blood Pressure
Register for Updates
The PulsePoint Study
NCT04806958
Recruiting
This randomized controlled trial will evaluate whether use of the PulsePoint system increases bystander CPR or defibrillator use compared to standard dispatch procedures in patients who suffer non-traumatic, out-of-hospital cardiac arrest in a public location. Half of all suspected cardiac arrest 9-1-1 calls in a public location will receive PulsePoint alerts (treatment arm). The other half of this eligible patient cohort will receive standard dispatch procedures (control arm).
Gender:
All
Ages:
All
Trial Updated:
06/28/2023
Locations: Columbus Division of Fire, Columbus, Ohio +2 locations
Conditions: Out-Of-Hospital Cardiac Arrest, Heart Arrest, Heart Diseases, Cardiovascular Diseases
Register for Updates
Development of CIRC Technologies
NCT05654272
Recruiting
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which mark... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cardiovascular Innovation Research Center, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Register for Updates
CV Imaging of Metabolic Interventions
NCT05650307
Recruiting
Cardiovascular disease is the leading cause of death worldwide. It is becoming clearer that heart failure (HF) is closely associated with body's metabolism. Even before the heart becomes weaker, it responds to the stresses by changing the fuels it burns, which results in a reduction in the heart's metabolic efficiency that worsens the heart's condition. Since the heart burns so much fuel and consumes fats and carbohydrates along with other available substrates, any changes in its metabolic effic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cardiovascular Innovation Research Center, Cleveland, Ohio
Conditions: Bariatric Surgery Candidate, Heart Failure, Cardiovascular Diseases
Register for Updates
Vascular Lab Resource (VLR) Biorepository
NCT05628948
Recruiting
This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular diseas... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/24/2023
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Register for Updates
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
NCT05919342
Recruiting
This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.
Gender:
All
Ages:
40 years and above
Trial Updated:
08/02/2023
Locations: Cleveland Clinic, Cleveland, Ohio +6 locations
Conditions: Heart Failure, Cardiovascular Diseases
Register for Updates
Zinc Effect on Inflammation and Cardiovascular Risk in HIV
NCT05085834
Recruiting
To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
06/28/2023
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Inflammation, Cardiovascular Diseases, Zinc Deficiency
Register for Updates
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Central Phoenix Medical Clinic, Phoenix, Arizona +164 locations
Conditions: Obesity, Cardiovascular Diseases
Register for Updates
Diabetes and Heart Disease Risk in Blacks
NCT00001853
Recruiting
It is unknown if obesity contributes to the development of heart disease in African American men and women. This study was created to determine whether there is a relationship between sex and body size and the incidence of heart disease in African American men and women. Researchers will attempt to associate obesity with the presence of heart disease risk factors. Risk factors that will be studied include; total body fat, body fat distribution, fat content of the blood (triglyceride concentrati... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Diabetes, Obesity, Hypertension, Cardiovascular Diseases
Register for Updates
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Alliance for Multispecialty Research, LLC, Daphne, Alabama +390 locations
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Register for Updates
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
NCT05642858
Recruiting
The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/17/2024
Locations: Zuckerberg San Francisco General Hospital, San Francisco, California +1 locations
Conditions: HIV, Human Immunodeficiency Virus, Cardiovascular Diseases, Atherosclerosis
Register for Updates